A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma
| 대상 질환 | Multiple Myeloma |
|---|---|
| 임상 단계 | 3상 |
| 스폰서 | Janssen Research & Development, LLC |
| 상태 | 진행 중(모집 완료) |
| 참여자 수 | 419 명 |
| 중재(약물) | Cilta-cel, Pomalidomide, Bortezomib, Dexamethasone, Daratumumab |
| 시작일 | 2020년 6월 12일 |
| 완료일 | 2024년 5월 1일 |
| 결과 공개일 | 2025년 5월 20일 |
요약
The purpose of this study is to compare the efficacy of ciltacabtagene autoleucel (cilta-cel) with standard therapy, either Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd).
Progression Free Survival (PFS)
| Arm A: Standard Therapy: PVd or DPd | 11.79 months |
|---|---|
| Arm B: JNJ-68284528 (Ciltacabtagene Autoleucel [Cilta-cel]) | NA months |
BENITIONS에서 보기 ClinicalTrials.gov 원문 보기
같은 질환의 다른 임상
- Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Mu — National Cancer Institute (NCI)
- Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Tr — National Cancer Institute (NCI)
- Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previo — National Cancer Institute (NCI)
- Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment fo — University of Michigan Rogel Cancer Center
- Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) a — University of Alabama at Birmingham
- Pembrolizumab in Treating Patients With Intermediate or High-Risk Smoldering Multiple Myel — M.D. Anderson Cancer Center